Aratana Therapeutics Inc (PETX)

8.70
0.53 5.70
NASDAQ : Health Care
Prev Close 9.23
Open 9.17
Day Low/High 8.79 / 9.19
52 Wk Low/High 2.56 / 19.99
Volume 184.83K
Avg Volume 675.60K
Exchange NASDAQ
Shares Outstanding 35.42M
Market Cap 331.49M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

4 Momentum Stocks You Should Watch Now

4 Momentum Stocks You Should Watch Now

Here are four stocks to watch with strong technical momentum.

Shark Bites: Aratana Therapeutics and Gigamon Are Fresh Additions

Shark Bites: Aratana Therapeutics and Gigamon Are Fresh Additions

The action in the indices is poor; I'll manage positions closely.

Short Interest In Aratana Therapeutics Decreases By 15%

Short Interest In Aratana Therapeutics Decreases By 15%

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 706,816 share decrease in total short interest for Aratana Therapeutics, Inc , to 4,048,011, a decrease of 14.87% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

October 21st Options Now Available For Aratana Therapeutics (PETX)

October 21st Options Now Available For Aratana Therapeutics (PETX)

Investors in Aratana Therapeutics, Inc saw new options begin trading today, for the October 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PETX options chain for the new October 21st contracts and identified one put and one call contract of particular interest.

3 Little Stocks With Big Upside

3 Little Stocks With Big Upside

Some small caps I own are on the move of late, and are still attractive.

Aratana Therapeutics Granted FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Aratana Therapeutics Granted FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Local Post-Operative Analgesia to Provide Extended Pain Control

It May Be Dull, but That's No Reason to Be Negative

It May Be Dull, but That's No Reason to Be Negative

Bears continue to have a tough time gaining traction.

Think Big on These Small Biotechs

Think Big on These Small Biotechs

New drugs give small-cap companies opportunity to expand markets and revenues.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Buyers Are Finding Support Despite Negative Breadth

Buyers Are Finding Support Despite Negative Breadth

There is still some good speculative action out there.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Aratana Therapeutics Files For FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Aratana Therapeutics Files For FDA Approval Of NOCITA® (bupivacaine Liposome Injectable Suspension)

Local Post-Operative Analgesia Provides Extended Pain Control

4 Stocks With Strong Technicals That You Should Watch

4 Stocks With Strong Technicals That You Should Watch

Here are four stocks with good technical strength pointing to higher prices.

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Trade-Ideas LLC identified Aratana Therapeutics (PETX) as a strong on high relative volume candidate

Aratana Therapeutics Receives CMC Technical Section Complete Letter For Post-Operative Pain Therapeutic

Aratana Therapeutics Receives CMC Technical Section Complete Letter For Post-Operative Pain Therapeutic

Final Major Technical Section Complete Letter for NOCITA® (bupivacaine liposome injectable suspension)

2 Promising Biopharmas Reach Key Junctures

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

Aratana Therapeutics Granted FDA Approval Of ENTYCE® (capromorelin Oral Solution)

Aratana Therapeutics Granted FDA Approval Of ENTYCE® (capromorelin Oral Solution)

First-of-its-Kind Ghrelin Mimetic

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Aratana Therapeutics (PETX) Is Strong On High Volume Today

Trade-Ideas LLC identified Aratana Therapeutics (PETX) as a strong on high relative volume candidate

2 Small-Cap Stocks That Could Win Big

Investing in small-cap names take a lot of research and patience, but they can also be very rewarding.

Aratana Therapeutics To Discuss Global Strategic Collaboration With Elanco Animal Health

Aratana Therapeutics To Discuss Global Strategic Collaboration With Elanco Animal Health

Conference Call Today at 6:00 p.m. ET

Aratana, Elanco Announce Global Strategic Collaboration

Aratana, Elanco Announce Global Strategic Collaboration

Agreement to expand Elanco's companion animal portfolio, extend global reach of GALLIPRANT® (grapiprant tablets) in canine osteoarthritis therapy